Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: life extension – Page 417

Why AI Will Be the Best Tool for Extending Our Longevity

Dmitry Kaminskiy speaks as though he were trying to unload everything he knows about the science and economics of longevity—from senolytics research that seeks to stop aging cells from spewing inflammatory proteins and other molecules to the trillion-dollar life extension industry that he and his colleagues are trying to foster—in one sitting.

At the heart of the discussion with Singularity Hub is the idea that artificial intelligence will be the engine that drives breakthroughs in how we approach healthcare and healthy aging—a concept with little traction even just five years ago.

“At that time, it was considered too futuristic that artificial intelligence and data science … might be more accurate compared to any hypothesis of human doctors,” said Kaminskiy, co-founder and managing partner at Deep Knowledge Ventures, an investment firm that is betting big on AI and longevity.

Dr Aubrey de Grey | Investing in the Age of Longevity 2019

Rejuvenation Biotechnology: on track to be the biggest industry ever.

Dr Aubrey de Grey, CSO at the SENS Research Foundation speaking at Master Investor’s Investing in the Age of Longevity 2019 event. Aubrey discusses Rejuvenation biotechnology and how it’s on track to become the biggest industry ever.

Master Investor is an investment media and events company that delivers independent, financial commentary and analysis to UK private investors and traders through events, magazines, news, blogs, podcasts and daily/weekly newsletters.
Read our latest magazine at www.masterinvestor.co.uk/magazine
Book a free ticket (use code MIYT) to attend the annual Master Investor Show (28th March 2020): https://masterinvestorshow-2020.reg.buzz
Keep in touch:
Newsletter | https://masterinvestor.co.uk/subscribe
Twitter | https://twitter.com/masterinvestor
Facebook | https://facebook.com/masterinvestor
LinkedIn | https://www.linkedin.com/company/masterinvestor

3 Aging Experts Tell How They Decided on Where to Grow Older

One of the most vexing questions many of us face once we hit our 60s is: Where should we live as we get older? I’m not talking about those “Best Places to Live” rankings. I mean what kind of home, and type of community, would be most suitable. That’s why I was eager to hear what several gerontologists had to say in their session at last week’s Gerontological Society of America conference about how they decided where they’d live in later life.

What kind of home and community is most suitable? The answer isn’t always rational.

Reason | Investing in the Age of Longevity 2019

Gene therapies to reverse immunosenescence and atherosclerosis.

CEO of Repair Biotechnologies speaking at Master Investor’s Investing in the Age of Longevity 2019 event. Reason discusses gene therapies to reverse immunosenescence and atherosclerosis.

Master Investor is an investment media and events company that delivers independent, financial commentary and analysis to UK private investors and traders through events, magazines, news, blogs, podcasts and daily/weekly newsletters.

Read our latest magazine at www.masterinvestor.co.uk/magazine

Book a free ticket (use code MIYT) to attend the annual Master Investor Show (28th March 2020): https://masterinvestorshow-2020.reg.buzz

Keep in touch:

Continue reading “Reason | Investing in the Age of Longevity 2019” | >

Epigenetic Aging: Can It Be Slowed With Diet?

New post!

Having a faster rate of epigenetic aging, as measured by the epigenetic age metric, AgeAccelGrim, is associated with a significantly increased risk of death for all causes in a variety of cohorts, including the Framingham Heart Study (FHS), the Women’s Health Initiative (WHI) study, the InChianti study, the Jackson Heart Study (JHS), and collectively, when evaluated as a meta-analysis (Lu et al. 2019):

Screen Shot 2019-12-07 at 2.23.27 PM.png

With the goal of minimizing disease risk and maximizing longevity, can epigenetic aging be slowed? Shown below is the correlation between dietary components with AgeAccelGrim. Dietary factors that were significantly associated (the column labelled, “p”) with a younger epigenetic age were carbohydrate intake, dairy, whole grains, fruit, and vegetables. In contrast, dietary fat intake and red meat were associated with older epigenetic ages (Lu et al. 2019):

Families with long, healthy life spans focus of $68 million grant

Families with long, healthy life spans focus of $68 million grant~ via Washington University School of Medicine in St. Louis https://medicine.wustl.edu/news/families-with-long-healthy-l…ion-grant/

A few hundred of the thousands of proteins circulating in our blood turn out to be a fairly accurate forecaster of a person’s age, scientists reported Thursday — though one’s biological age, which doesn’t always match one’s number of years.

This “proteomic clock,” as the researchers call it, relies on measurements of levels of the proteins, which rise and fall over the years. While it’s a nifty discovery, for now it remains just that. Researchers need to first develop a much better understanding of these proteins; if they can, they said, it might be possible to one day look at their levels to gauge the success of drugs being tested in clinical trials, or even to develop a therapy from a cocktail of proteins that could act like a rejuvenation boost or improve health.

“Why are these proteins so tightly linked to aging?” said Tony Wyss-Coray, professor of neurology and neurological sciences at Stanford and the senior author of the paper4, which was published Thursday in the journal Nature Medicine.

Scientists develop a ‘clock’ to measure biological age based on blood

A few hundred of the thousands of proteins circulating in our blood turn out to be a fairly accurate forecaster of a person’s age, scientists reported Thursday — though one’s biological age, which doesn’t always match one’s number of years.

This “proteomic clock,” as the researchers call it, relies on measurements of levels of the proteins, which rise and fall over the years. While it’s a nifty discovery, for now it remains just that. Researchers need to first develop a much better understanding of these proteins; if they can, they said, it might be possible to one day look at their levels to gauge the success of drugs being tested in clinical trials, or even to develop a therapy from a cocktail of proteins that could act like a rejuvenation boost or improve health.

“Why are these proteins so tightly linked to aging?” said Tony Wyss-Coray, professor of neurology and neurological sciences at Stanford and the senior author of the paper4, which was published Thursday in the journal Nature Medicine.

/* */